I agree she knows, too bad nobody showed a statement from her regarding that, so it’s just a conjecture.I would think Rui-ping would know, but ok
I agree she knows, too bad nobody showed a statement from her regarding that, so it’s just a conjecture.I would think Rui-ping would know, but ok
They did. They showed an email from herI agree she knows, too bad nobody showed a statement from her regarding that, so it’s just a conjecture.
Literally right below that paragraph, they say that their first indication for the primary drug is Androgenetic Alopecia (female and male) and endo. You do this all the time on here, you cherry pick information and in this case it's literally one paragraph later. No one is saying that the company was formed to be a hair loss company, they're trying to be a major biotech company that specializes in treatment pathways involving prolactin, which touches on some major womens health issues such as cancer. This doesn't change that hair loss is listed as one of two primary indications. I see why you would think this is comparable to Samumed, but the difference is that this company was formed and subsequently funded based on the licensing agreement with Bayer after preclinical work for hairloss was already completed. Samumed said they had the cure to all diseases and raised a lot of money from unqualified investors, not top tier biotech venture funds.Lol and do you think Hopemed got $56 million dollar for their AA prolactin treatment? There isn't a lot of difference with samumed.
The focus of Hopemed isn't balding.
From press release:
HopeMed focuses on the three major disease areas of women's health, endocrine, and cardiovascular diseases
Hope Medicine completed US$56 million in Series B financing, strengthening capabilities of global innovation
SHANGHAI, May 6, 2021 /PRNewswire/ -- Recently, the global innovative drug R&D company Hope Medicine Inc. (referred to as "HopeMed") announced the completion of a Series B...www.asiaone.com
They didn't get the funding "just" for the hairloss treatment, they got funding because the people who invested in them think they can be a massive biotech company and hairloss just so happens to be one of the first of many indications they will pursue. Unless you're dealing with incredibly niche fields (like Stemson is with cloning), most biotech startups are going to hope to offer their therapies for a wide range of indications.Still doubt they got all this funding purely because of their hairloss treatment... But hey I'm not going to piss in your cornflakes anymore, I hope this turns out to be legit too.
To an extent. If not for hair loss they wouldn't have another pipeline. There's little evidence that it will work for endometriosis, so that's a gamble. The NHP model shows that it works for hair loss, so that's the nearly sure bet. That also makes bph and pc a strong possibility when combined with the research on that, and the link between bph and hair loss. Likely the thought process of the investors was, "worst case scenario we have a working hair loss drug, and we will get our investment back with a profit. If the drug works in other conditions, and the rest of their pipeline proves out then we have a gold mine." That would be my reasoning behind investing at least. Without the observational evidence behind hair loss the investment becomes a lot more speculative.They didn't get the funding "just" for the hairloss treatment, they got funding because the people who invested in them think they can be a massive biotech company and hairloss just so happens to be one of the first of many indications they will pursue. Unless you're dealing with incredibly niche fields (like Stemson is with cloning), most biotech startups are going to hope to offer their therapies for a wide range of indications.
Hairloss is also easily the least profitable indication that they will pursue even if they outright cure it with HMI115, and for that reason they probably would not have gotten this funding without other indications. This is why many larger biotech companies like Bayer would rather license something like this out then develop it in house.
Someone could get in touch with him and ask if he can tell us the main points that was shared during the Stemson presentation .I just finished us with Global Hair Loss Summit 2021 where I oversaw the production of over 70 videos submitted by 60 plus physicians from around the world, including content from Stemson Therapeutics and specialists in the fields of regenerative medicine, hair transplant surgery and more.
low how they have to wct as if malr pwttern bsldness ie the most minor issues and they are really doing it to the ppor womenzz who get alopecia areata or chemo therapy, male pattern baldness is JUST an inconvenience. if it was women whos appearance just got degenerated at 20 purely based on luvk itd be a different story
They do it for marketing purposes. If it's not obvious by now, people in general dont care about male pattern baldness. If you add women & people with other serious conditions to the treatment target base you get a lot more attention, as women are actually just as large of a market size as men when it comes to thinning hair, they just don't lose it entirely in most cases so it doesn't seem as obvious.low how they have to wct as if malr pwttern bsldness ie the most minor issues and they are really doing it to the ppor womenzz who get alopecia areata or chemo therapy, male pattern baldness is JUST an inconvenience. if it was women whos appearance just got degenerated at 20 purely based on luvk itd be a different story
so whx make a product at all? they coule be doing spinal cord treatment with IPC but they chose to focus on this issue that mostly affects men. i think their attrmpts to cure scarring alopecia or areata is even hsrder because with androgenic slopecia you just havr to address the sndrogen sensitivity problem, with other cinditions you havr auto immune issues to address so the cloned hair doesnt just fall out. where is there money coming from?They do it for marketing purposes. If it's not obvious by now, people in general dont care about male pattern baldness. If you add women to the treatment target base you get a lot more attention.
I don't have time to explain to you how the venture capital game works, but in short, the larger the market size you are targeting the better your odds of getting attention, scale and funding.so whx make a product at all? they coule be doing spinal cord treatment with IPC but they chose to focus on this issue that mostly affects men. i think their attrmpts to cure scarring alopecia or areata is even hsrder because with androgenic slopecia you just havr to address the sndrogen sensitivity problem, with other cinditions you havr auto immune issues to address so the cloned hair doesnt just fall out. where is there money coming from?
I agree. The only thing that disappointed me in this video was when he said they were talking to industry partners in robotics. That basically means they are talking to ARTAS and I don't think anyone should want one of those existing things touching their heads. That's not to say they wont be getting more advanced systems in place, but I thought they were doing the technology in-house.Interesting presentation. Shame no one had any questions. It sounds like they've already had success in pig trials and think they will be ready for human trials soon. That's a lot more optimistic than what we last heard from them. I'm glad they are going with the autologous approach first, as that will be easier to get approved and I'd prefer that anyway.
i mean you can do an artist job at the hairline and artas at the crown and nobody is fonna notice and it will be aestetically pleasing. people have ridiculous standards, i realized this when people talk about densitity and whether they csn get this and that density natural density blablabla, who gibes a f***, all the matter is to have a decent amount of coverage and a natural hairlineI agree. The only thing that disappointed me in this video was when he said they were talking to industry partners in robotics. That basically means they are talking to ARTAS and I don't think anyone should want one of those existing things touching their heads. That's not to say they wont be getting more advanced systems in place, but I thought they were doing the technology in-house.